Orchestra BioMed Holdings, Inc. OBIO 深 滬
已收盤 04-24 16:00:00 美东时间
4.13
-0.020
-0.48%
華盛通- 最 高4.22
- 今 開4.14
- 成交量 25.24万股
- 最 低 4.005
- 昨 收 4.15
- 總市值 2.42亿
- 52周最高 5.424
- 市盈率 靜 --
- 換手率 0.43%
- 52周最低 2.20
- 委 比 -42.93%
- 總股本 5852.09万
- 歷史最高 23.39
- 量 比 1.67
- 振 幅 5.18%
- 歷史最低 2.20
- 每 手 1
- 風險率 0.78%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Orchestra BioMed Hldgs Q4 EPS $0.26 Beats $(0.39) Estimate, Sales $30.917M Beat $878.600K Estimate
Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $(0.39) by 166.16 percent. This is a 160.47 percent increase over losses of $(0.43) per
03-12 20:35
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
Barclays Maintains Overweight on Orchestra BioMed Hldgs, Raises Price Target to $12
Barclays analyst Matt Miksic maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and raises the price target from $11 to $12.
01-09 23:09
美股大行评级 | 超配！大摩上调回声星通信评级；汽车地带、CBRL、金宝汤、家得宝等遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8美元升至8.25美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12.5美元升至13美元
2025-12-11 10:33
TD Cowen Initiates Coverage On Orchestra BioMed Hldgs with Buy Rating, Announces Price Target of $15
TD Cowen analyst Joshua Jennings initiates coverage on Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy rating and announces Price Target of $15.
2025-12-11 00:03
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
2025-11-14 10:43
美股大行评级 | 富国银行上调AMD目标价升至345美元；花旗上调礼来目标价升至1500美元；巴克莱上调腾讯音乐目标价升至28美元
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从12美元升至15美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从106美元升至107美元
2025-11-13 09:58
Barclays Maintains Overweight on Orchestra BioMed Hldgs, Lowers Price Target to $11
Barclays analyst Matt Miksic maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and lowers the price target from $12 to $11.
2025-11-12 23:57
Orchestra BioMed Hldgs Q3 EPS $(0.40) Beats $(0.42) Estimate, Sales $861.000K Beat $757.600K Estimate
Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.42) by 5.21 percent. This is a 2.44 percent increase over losses of $(0.41) per share
2025-11-11 05:32
Orchestra BioMed Announces Strategic Agreement with Terumo
Orchestra BioMed Holdings ( ($OBIO) ) just unveiled an update. On October 28, 2...
2025-10-28 20:26
